(NASDAQ: AZN) Astrazeneca's forecast annual revenue growth rate of 6.85% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Astrazeneca's revenue in 2024 is $47,611,000,000.On average, 4 Wall Street analysts forecast AZN's revenue for 2024 to be $79,013,523,679,198, with the lowest AZN revenue forecast at $77,998,261,719,089, and the highest AZN revenue forecast at $79,558,996,454,198. On average, 4 Wall Street analysts forecast AZN's revenue for 2025 to be $85,252,252,377,944, with the lowest AZN revenue forecast at $84,598,575,151,324, and the highest AZN revenue forecast at $85,906,780,643,845.
In 2026, AZN is forecast to generate $89,732,299,875,215 in revenue, with the lowest revenue forecast at $88,188,751,793,140 and the highest revenue forecast at $91,516,755,630,671.